Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Maddy - GI II Exam I - some pharm > Pharm - Anti Nausea/Vomiting > Flashcards

Pharm - Anti Nausea/Vomiting Flashcards

1
Q

list the serotonin (5-HT3) receptor antagonists

A
  • dolasetron
  • granisetron
  • ondansetron
  • palonosetron
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

-pitant ending indicates what drug

A

neurokinin (NK1) receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

-setron ending indicates what drug

A

serotonin (5-HT3) receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

list the histamine (H1) receptor antagonists

A
  • diphenydramine
  • dimenhydrinate
  • hydroxyzine
  • promethazine
  • meclizine
  • cyclizine
  • doxylamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

list the dopamine (D2) receptor antagonists

A
  • chlorpromazine
  • perphenazine
  • prochlorperazine
  • metoclopramide
  • haloperidol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

list the muscarinic (M1) receptor antagonist

A

scopolamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

list the cannabinoid receptor agonists

A
  • dronabinol

- nabilone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MOA of serotonin (5-HT3) receptor antagonists

A

blocks serotonin type-3 receptors at the vagal nerve terminal and blocks signal transmission to chemoreceptor trigger zone

(blocks serotonin-receptor activation after serotonin release from intestinal enterochromaffin cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

therapeutic uses of serotonin (5-HT3) receptor antagonists

A
  • chemotherapy induced N/V
  • radiation-induced N/V
  • post-operative N/V
  • N/V of pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

adverse effects of serotonin (5-HT3) receptor antagonists

A
  • headaches
  • constipation/diarrhea (serotonin syndrome)
  • dose-dependent QT prolongation (torsades)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

extreme caution should be used when prescribing serotonin (5-HT3) receptor antagonists with _____

A

QT prolonging agents

- antiarrhythmics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what patients should not be prescribed serotonin (5-HT3) receptor antagonists

A

hypokalemic and hypomagnesmic patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

half life of serotonin (5-HT3) receptor antagonists

A

all have short half-lives EXCEPT palonosetron and sustained-release formulation of granisetron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what serotonin (5-HT3) receptor antagonists should be used for delayed chemotherapy induced N/V as a single dose

A
  • palonosetron (long half life)
  • 2 branded-granisetron agents (long half life)
  • sustol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

therapeutic uses of neurokinin-1 receptor antagonists

A
  • chemotherapy induced N/V

- prophylaxis of post-operative N/V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the only NK1 antagonist that should be used prophylactically for post-operative N/V

A

aprepitant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

to treat chemotherapy induced N/V, NK1 antagonists should be used in combination with ____

A

a glucocorticosteroid and 5-HT3 antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

adverse effects of NK1 antagonists

A
  • dyspepsia/constipation/diarrhea

- dizziness/fatigue/somnolence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what NK1 antagonists have longer half lives

A
  • netupitant

- rolapitatant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what drug interactions can occur with NK1 antagonists

A

many - it’s a cyp450 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

MOA of H1 receptor antagonists

A

block histamine type 1 receptors in the vomiting center and vestibular system
- varying levels of anticholinergic properties at the level of chemoreceptor trigger zones

22
Q

therapeutic uses of H1 receptor antagonists

A
  • idiopathic, mild N/V
  • post-operative N/V
  • N/V of pregnancy
  • motion sickness/vertigo
  • chemotherapy induced N/V
  • radiation induced n/V
23
Q

what is the only indication for meclizine and cyclizine (H1 receptor antagonists)

A

motion sickness/vertigo

24
Q

therapeutic use of doxylamine (H1 receptor antagonist) with pyridoxine (B6)

A

N/V of pregnancy

25
adverse effects H1 receptor antagonists
- drowsiness - dry mouth - constipation - urinary retention - blurred vision - decreased BP (classic anticholinergic effects)
26
drug interactions with H1 receptor antagonists
interactions with other agents that also induce anticholinergic related side effects
27
MOA of dopamine (D2) receptor antagonists
block dopamine type 2 receptors in the chemoreceptor trigger zone - agents exhibit varying levels of anticholinergic properties
28
MOA of metoclopramide, other than the normal MOA of other dopamine (D2) receptor antagonists
it also stimulates acetycholine actions in the GI tract --> enhances GI motility and increases lower esophageal sphincter tone - no impact on GI secretions
29
which dopamine (D2) receptor antagonist can be used to treat diabetic gastroparesis/dysmotility
metoclopramide
30
therapeutic uses of dopamine (D2) receptor antagonists
- idiopathic, mild N/V - gastroparesis/dysmotility (metoclopramide) - post operative N/V - N/V of pregnancy - chemotherapy induced N/V - radiation induced N/V
31
adverse effects of dopamine (D2) receptor antagonists
- drowsiness - dry mouth - constipation - urinary retention - blurred vision - decreased BP (sometimes arrhythmias) (classic anticholinergic effects)
32
drug interactions with dopamine (D2) receptor antagonists
- other agents w/ anticholinergic effects - antiarrhythmics - antihypertensives
33
how is scopolamine administered
transderm scop (a patch worn for 72 hours, normally placed behind ear)
34
therapeutic uses for scopolamine
motion sickness | - also end of life care for excessive secretions
35
MOA scopolamine
block acetycholine-stimulated muscarinic receptors in neural pathways from the vestibular nuclei in the inner ear --> brain stem and from the reticular formation --> vomiting center - significant anticholinergic properties
36
adverse effects scopolamine
- drowsiness - dry mouth - constipation - urinary retention - blurred vision (classic anticholinergic effects, but does not drop BP)
37
drug interactions scopolamine
other agents that induce anticholinergic effects
38
therapeutic uses cannabinoids
- treatment-resistance chemotherapy-induced N/V | - appetite stimulation in anorexic patients due to severe disease (cancer, AIDS)
39
MOA cannabinoids
stimulate CB1 and CB2 receptors in the vomiting center/chemoreceptor trigger zone - exert signal transduction effects through GPCR --> decreased excitability of neurons - minimized serotonin release from vagal afferent terminals
40
adverse effects cannabinoids
- euphoria/irritability - vertigo - sedation/drowsiness - impaired cognition/memory - hallucinations - xerostomia - sympathomimetic (increased HR/BP) - appetite sitmulation
41
compare pharmacokinetics of dronabinol and nabilone
dronabinol: large first pass effect and metabolized to one active metabolite nabilone: metabolized to several active metabolites
42
drug interactions with cannabinoids
use caution when prescribing with other CNS depressants, cardiovascular agents, and sympathomimetics
43
compare acute, chronic, and anticipatory chemotherapy induced N/V
acute: occurs less than 24 hrs after chemo chronic: occurs more than 24 hrs after chemo anticipatory: occurs before chemo
44
describe the high-emetogenic regiment (3-drug regimen) for chemotherapy induced N/V
1. NK1 receptor antagonist 2. 5-HT3 receptor antagonist 3. Corticosteroid (dexamethasone) give regimen the day of the chemo (for acute N/V) and for 3 days after chemo (for chronic)
45
what can you add to the high-emetogenic (3 drug regimen) to form the 4 drug regimen
- may add olanzapine (D2 antagonist) | - may add cannabinoid in treatment-resistance
46
describe the moderate-emetogenic regiment (2 drug regimen)
1. 5-HT3 receptor antagonist 2. Corticosteroid (dexamethasone) give regimen the day of the chemo (for acute N/V) and for 2 days after chemo (for chronic)
47
what can you add to the moderate-emetogenic (2 drug regimen) to form the 3 drug regimen
- may add NK1 antagonist or olanzapine | - may add cannabinoid in treatment resistance
48
describe the low-emetogenic regiment (1 drug regimen)
One of the following: 1. corticosteroid 2. 5-HT3 receptor antagonist 3. metoclopramide 4. prochlorperazine give regimen day of (prior to) chemotherapy (for acute N/V)
49
describe the minimal-emetogenic regiment (0 drug regimen)
1. no routine prophylaxis therapy recommended
50
describe the general principle of the breakthrough emesis regiment
add one agent from a different drug class to the current regimen
51
describe the stepped-therapy for pregnancy induced N/V
1. vitamin B6 OR histamine antagonist w/ B6 OR 5-HT3 2. dopamine antagonist 3. steroid OR different dopamine antagonist

Maddy - GI II Exam I - some pharm (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions